The Gross Margin of AbbVie Inc. (ABBV) is
71.62%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
71.62%
|
| 2024-12-31 |
69.99%
|
| 2023-12-31 |
66.45%
|
| 2022-12-31 |
71.53%
|
| 2021-12-31 |
69.19%
|
| 2020-12-31 |
66.69%
|
| 2019-12-31 |
77.14%
|
| 2018-12-31 |
76.93%
|
| 2017-12-31 |
75.89%
|
| 2016-12-31 |
77.32%
|
| Ticker |
Name |
Value |
|
AGIO
|
Agios Pharmaceuticals, Inc.
|
88.26%
|
|
ARWR
|
Arrowhead Pharmaceuticals, Inc.
|
100.00%
|
|
BIIB
|
Biogen Inc.
|
75.99%
|
|
TWST
|
Twist Bioscience Corporation
|
50.72%
|
|
AMRN
|
Amarin Corporation PLC
|
56.57%
|
|
EDIT
|
Editas Medicine, Inc.
|
7775.20%
|
|
EXAS
|
Exact Sciences Corporation
|
69.69%
|
|
NTRA
|
Natera, Inc.
|
64.75%
|
|
XNCR
|
Xencor, Inc.
|
7775.20%
|
|
ALLK
|
Allakos LLC
|
7775.20%
|
|
ALXN
|
Alexion Pharmaceuticals Inc
|
90.88%
|
|
BMRN
|
BioMarin Pharmaceutical Inc.
|
81.43%
|
|
EXEL
|
Exelixis Inc
|
96.39%
|
|
NVAX
|
Novavax, Inc.
|
93.50%
|
|
MYGN
|
Myriad Genetics, Inc.
|
69.93%
|
|
VCEL
|
Vericel Corporation
|
74.42%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
CBPO
|
China Biologic Products Holdings Inc
|
65.68%
|
|
VIR
|
Vir Biotechnology, Inc.
|
99.96%
|
|
ACAD
|
Acadia Pharmaceuticals Inc.
|
91.69%
|
|
BBIO
|
BridgeBio Pharma, Inc.
|
95.82%
|
|
CHRS
|
Coherus Oncology Inc
|
67.24%
|
|
INSM
|
Insmed Incorporated
|
79.73%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
75.62%
|
|
NBIX
|
Neurocrine Biosciences, Inc.
|
98.18%
|
|
OPK
|
OPKO Health, Inc.
|
36.84%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
46.82%
|
|
PTCT
|
PTC Therapeutics, Inc.
|
97.28%
|